SANN Share Price Performance
CHF 10.72
2.69 (33.50%)
Price CHF 10.72
Share Pricen/a
Investors Don't See Light At End Of Santhera Pharmaceuticals Holding AG's (VTX:SANN) Tunnel And Push Stock Down 26%
Oct 07
Santhera Pharmaceuticals Holding AG Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
SANN Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Santhera Pharmaceuticals Holding AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -4.90
- 13.41%
- -133.72%
- -1,520.4%
About SANN
- Founded
- 2004
- Employees
- 79
- CEO
- WebsiteView website
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
